Literature DB >> 31857832

Modulation of Tropomyosin Receptor Kinase for the Treatment of Neurotrophin Diseases: Alzheimer's, Huntington's and Parkinson's.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2019        PMID： 31857832      PMCID： PMC6912868          DOI： 10.1021/acsmedchemlett.9b00506

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

Review 1.  Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.

Authors:  Subrata Pramanik; Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

Review 2.  Larotrectinib: First Global Approval.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 3.  Targeting TRK family proteins in cancer.

Authors:  Yekaterina B Khotskaya; Vijaykumar R Holla; Anna F Farago; Kenna R Mills Shaw; Funda Meric-Bernstam; David S Hong
Journal:  Pharmacol Ther       Date:  2017-02-04       Impact factor: 12.310

Review 4.  Neuroprotective effects of exercise in rodent models of memory deficit and Alzheimer's.

Authors:  Zahra Jahangiri; Zahra Gholamnezhad; Mahmoud Hosseini
Journal:  Metab Brain Dis       Date:  2018-11-15       Impact factor: 3.584

Review 5.  Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer.

Authors:  Derek Wong; Stephen Yip; Poul H Sorensen
Journal:  Pathol Oncol Res       Date:  2019-06-29       Impact factor: 3.201
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.